title: Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
abstract: Purified approximately 54 kDa plasminogen activator inhibitor from human fibrosarcoma cells was converted to an inactive form with slightly higher electrophoretic mobility by incubation with catalytic amounts of urokinase-type or tissue-type plasminogen activator. Serine proteinase inhibitors and a monoclonal antibody against urokinase-type plasminogen activator inhibited the conversion, indicating that it was caused by plasminogen activator-catalyzed proteolysis. These findings represent the first demonstration of a well-defined protein apart from plasminogen, constituting a substrate for plasminogen activators.
authors.forename: L S
authors.initials: LS
authors.lastname: Nielsen
authors.forename: P A
authors.initials: PA
authors.lastname: Andreasen
authors.forename: J
authors.initials: J
authors.lastname: Grøndahl-Hansen
authors.forename: L
authors.initials: L
authors.lastname: Skriver
authors.forename: K
authors.initials: K
authors.lastname: Danø
mesh_terms: D002460:Cell Line; D005354:Fibrosarcoma / Q000378:metabolism*; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D008970:Molecular Weight; D010960:Plasminogen Activators / Q000378:metabolism*; D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
chemical_list: D006023:Glycoproteins; D015849:Plasminogen Inactivators; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator